AbbVie, Neurocrine End One Orilissa Patent Case Against Hetero

AbbVie Inc. and Neurocrine Biosciences Inc. agreed to end their federal lawsuit alleging Hetero Labs Ltd.'s proposed copies of the endometriosis drug Orilissa infringe a newer formulation patent, narrowing a broader dispute involving earlier patents.

The plaintiffs won’t sue Hetero over US Patent No. 12,102,637 so long as Hetero doesn’t change the generic’s formulation and other key characteristics, according to an order of dismissal issued Tuesday in the US District Court for the District of Delaware. Neurocrine owns the patent, issued in October 2024, and licenses it to AbbVie.

Hetero is the last remaining defendant of nine that were targeted ...